Cullinan Therapeutics (CGEM) CLO adds 2,470 ESPP shares at $8.60
Cullinan Therapeutics' Chief Legal Officer, Jacquelyn L. Sumer, acquired 2,470 shares of common stock at $8.60 per share through the company's 2021 Employee Stock Purchase Plan. This routine transaction, which occurred between January 1 and June 30, 2026, increases her direct holdings to 130,559 shares. The shares were purchased at 85% of the closing price on January 2, 2026, and the transaction is exempt under Rule 16b-3(c).
Cullinan Therapeutics (CGEM) CFO adds 1,541 shares through ESPP purchase
Cullinan Therapeutics' CFO, Mary Kay Fenton, acquired 1,541 shares of company common stock through the 2021 Employee Stock Purchase Plan. The shares were purchased at $8.60 each, based on 85% of the closing price on January 2, 2026, for the period of January 1 to June 30, 2026. Following this transaction, Fenton directly holds 127,921 shares of Cullinan Therapeutics common stock.
EGFR-NSCLC Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innovative Medicine
The EGFR-NSCLC market is projected to grow significantly, from USD 7.0 billion in 2025 to USD 16.0 billion by 2036, driven by targeted therapies and advancements in treatment. Key companies like AstraZeneca, J&J, and others are actively developing and launching therapies such as amivantamab and osimertinib, which are expected to generate the highest revenues. The report highlights emerging therapies, increasing biomarker testing, and a rich pipeline as market drivers, while cost-effectiveness and small patient populations pose potential barriers.
Cullinan Oncology stock hits 52-week high at $17.97 By Investing.com
Cullinan Oncology (CGEM) stock recently hit a 52-week high of $17.97, reflecting a significant 127.68% increase over the past year. Despite an InvestingPro analysis suggesting potential overvaluation, the company, with a $1.1 billion market capitalization, continues to show strong growth. Recent developments include positive clinical trial data, an Orphan Drug Designation from the FDA, and maintained "Buy" and "Outperform" ratings from analysts, highlighting confidence in its R&D.
Cullinan Therapeutics (CGEM) Is Up 31.0% After Autoimmune T Cell Engager Data – Has The Bull Case Changed?
Cullinan Therapeutics (CGEM) stock surged 31.0% after reporting positive Phase 1 data for its T cell engagers, CLN-978 and velinotamig, in autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus. This data indicates strong clinical responses and favorable safety, positioning the company to expand beyond oncology into treating chronic autoimmune conditions. While this strengthens Cullinan's investment narrative and upcoming readouts, the company remains loss-making and reliant on new capital, with potential dilution risks.
Understanding Momentum Shifts in (CGEM)
This article provides an in-depth analysis of Cullinan Oncology Inc. (CGEM) using AI models to identify momentum shifts and suggest trading strategies. It highlights strong sentiment across all time horizons supporting an overweight bias and points out that resistance is being tested. The analysis includes distinct strategies for different risk profiles, offering various entry and exit points, alongside support and resistance levels.
Cullinan Oncology stock hits 52-week high at $17.97
Cullinan Oncology LLC's stock reached a 52-week high of $17.97, and is currently trading just 1% below this peak. The company has recently reported positive clinical trial data, received Orphan Drug Designation for CLN-049, and held its Annual Meeting of Stockholders. Analysts from William Blair and Stifel have reiterated 'Outperform' and 'Buy' ratings, respectively, based on the company's research and development efforts.
Cullinan Oncology stock hits 52-week high at $17.97 By Investing.com
Cullinan Oncology's stock reached a 52-week high of $17.97, reflecting a 127.68% increase over the past year and strong investor confidence despite being potentially overvalued according to InvestingPro. The biotech firm, with a $1.1 billion market capitalization, continues to advance its drug candidates for autoimmune diseases and acute myeloid leukemia, supported by positive analyst ratings from William Blair and Stifel.
Cullinan Oncology stock hits 52-week high at $17.97 By Investing.com
Cullinan Oncology (CGEM) stock has reached a new 52-week high of $17.97, reflecting a 127.68% increase over the past year. Despite an InvestingPro analysis suggesting the stock may be overvalued, the company, with a market capitalization of $1.1 billion, continues to demonstrate strong growth and investor confidence, supported by positive clinical trial data and analyst ratings.
Cullinan Therapeutics (CGEM) Citi’s 2026 Virtual Oncology Leadership Summit Summary
Cullinan Therapeutics discussed its pipeline strategy at Citi’s 2026 Virtual Oncology Leadership Summit, highlighting T-cell engagers CLN-978 for autoimmune diseases and CLN-049 for AML as key catalysts for the year. The company aims for transformative potential with first-in-class or best-in-class molecules. CLN-049 showed promising monotherapy efficacy in AML, while zipalertinib for NSCLC is nearing NDA completion with a significant market opportunity.
Cullinan Therapeutics (CGEM) director receives 21,781-share stock option grant
Cullinan Therapeutics director Andrew R. Allen was granted stock options for 21,781 shares of common stock with an exercise price of $13.55 per share. These options will vest in full by June 16, 2027, or the company's next annual meeting, provided his continued board service. This grant is classified as a compensatory award and not an open-market transaction.
Cullinan Therapeutics (CGEM) grants director Mittie Doyle 21,781 stock options
Cullinan Therapeutics director Mittie Doyle was granted 21,781 stock options at an exercise price of $13.55 per share. The options will vest in full on the earlier of June 16, 2027, or the company's next annual meeting, provided she continues her service as a director. This transaction is classified as a compensation award rather than an open-market trade.
Cullinan Therapeutics (CGEM) director awarded 25,319 options at $13.55 strike
Cullinan Therapeutics director Mary Thistle was granted 25,319 stock options with an exercise price of $13.55 per share. The options will vest in full by June 16, 2027, or the company's next annual meeting, provided she continues her service as a director. This grant is part of her equity-based compensation and is tied to her ongoing role on the board.
Cullinan Therapeutics (CGEM) grants director 25,319 stock options
Cullinan Therapeutics (CGEM) director Anthony Rosenberg was granted 25,319 stock options with an exercise price of $13.55 per share. These options will vest in full by June 16, 2027, or at the company's next annual meeting, provided he continues his board service. The Form 4 filing reported no open-market buying or selling by Rosenberg, showing only this compensation grant.
Cullinan Therapeutics shareholders elect directors and approve proposals at annual meeting
Cullinan Therapeutics (NASDAQ: CGEM) shareholders elected two Class III directors for three-year terms, ratified KPMG LLP as the independent registered public accounting firm, and approved an advisory vote on executive compensation at their annual meeting. The biotech company has seen a 56% stock increase over the past year, with analysts maintaining a "strong buy" consensus. Recent news also highlights clinical trial data for autoimmune drug candidates and Orphan Drug Designation for CLN-049.
Director David D. Meek granted 25,319 options at Cullinan Therapeutics (CGEM)
Cullinan Therapeutics director David D. Meek was granted 25,319 stock options with an exercise price of $13.55 per share. These options will vest in full by June 16, 2027, or the date of the company's next annual meeting, contingent on his continued service as a director. This grant is part of his compensation and not an open-market purchase.
Cullinan Therapeutics (NASDAQ: CGEM) shareholders back directors, KPMG and pay
Cullinan Therapeutics (NASDAQ: CGEM) shareholders held their Annual Meeting on June 16, 2026, where they elected two Class III directors, Nadim Ahmed and Stephen Webster, to three-year terms. They also ratified KPMG LLP as the independent registered accounting firm for 2026 and approved the advisory vote on executive compensation for named executive officers. All three proposals received the required support from stockholders.
Avoiding Lag: Real-Time Signals in (CGEM) Movement
Cullinan Oncology Inc. (NASDAQ: CGEM) is showing weak near and mid-term sentiment but a strong long-term outlook, according to AI models. The article details three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss levels. It highlights an exceptional 60.3:1 risk-reward setup targeting a 19.0% gain versus 0.3% risk.
[8-K] Cullinan Therapeutics, Inc. Reports Material Event
Cullinan Therapeutics (NASDAQ: CGEM) has reported early-stage clinical data for its T cell engager programs CLN-978 and velinotamig, targeting autoimmune diseases. CLN-978 showed robust efficacy, including remission in a rheumatoid arthritis patient, and velinotamig demonstrated favorable safety and complete renal responses in systemic lupus erythematosus (SLE) patients. The company plans further data releases for both programs and new trial initiations in early 2027, indicating continued development in this therapeutic area.
Cullinan Therapeutics reports promising autoimmune trial data
Cullinan Therapeutics announced promising initial clinical data for its dual-targeting T-cell engager, CLN-978, showing its potential in autoimmune diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company reported clinical remissions and B-cell depletion in difficult-to-treat patients, with plans to expand its Phase 2a trial for lupus nephritis. This marks an expansion into the autoimmune space for the oncology-focused biotech.
Cullinan reports clinical data for autoimmune drug candidates
Cullinan Therapeutics Inc. reported promising clinical data for two T cell engager drug candidates, CLN-978 and velinotamig, targeting autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis. Despite a recent stock decline, the company saw positive patient responses and plans further data releases and trial expansions. Analysts maintain positive ratings, with some raising price targets, highlighting the potential of Cullinan’s pipeline.
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
Cullinan Therapeutics announced new clinical data from its T cell engager programs targeting CD19 (CLN-978) and BCMA (velinotamig) for autoimmune diseases. CLN-978 showed potential for immune reset and clinical remissions in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), with additional multi-dose data expected in Q3 and Q4 2026. Velinotamig demonstrated promising clinical activity, including complete renal responses in lupus nephritis, and is slated for a Phase 1/2a trial in autoimmune cytopenias in Q1 2027.
Cullinan Therapeutics (CGEM) posts early CLN-978 SLE and RA remission data
Cullinan Therapeutics reported initial Phase 1 data for CLN-978, a T cell engager, in treatment-refractory systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), showing meaningful clinical and biologic signals. In SLE, 71% of patients achieved a significant reduction in disease activity, with 5 reaching remission, and in RA, 71% showed improved disease activity. The drug demonstrated deep, dose-dependent B cell depletion without affecting protective vaccine titers and exhibited a generally well-tolerated safety profile at target doses up to 30 µg, with mostly Grade 1 cytokine release syndrome
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Cullinan Therapeutics presented initial Phase 1 clinical data for CLN-978, a CD19xCD3 T cell engager, at the EULAR 2026 Congress, demonstrating clinical benefit and remission in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The data showed deep, dose-dependent B cell depletion and a favorable safety profile. The company plans to share additional data, including from multi-dose regimens and initial clinical data for velinotamig, at its upcoming Immunology Day.
Discipline and Rules-Based Execution in CGEM Response
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM), identifying a near-term strong sentiment potentially shifting to neutral mid-term and positive long-term. It highlights an exceptional 63.5:1 risk-reward setup targeting a 16.9% gain with minimal risk and provides three AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging. The analysis is supported by multi-timeframe signals indicating support and resistance levels.
Discipline and Rules-Based Execution in CGEM Response
Cullinan Oncology Inc. (NASDAQ: CGEM) is showing strong near-term sentiment with a long-term positive bias, according to AI models. The analysis highlights a 63.5:1 risk-reward setup targeting a 16.9% gain with minimal risk. Three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—are provided, along with multi-timeframe signal analysis, to assist with various risk profiles and holding periods.
CGEM - Cullinan Therapeutics Inc Stock Price and Quote
Cullinan Therapeutics Inc. (CGEM) is a clinical-stage biopharmaceutical company focused on developing oncology and immuno-oncology therapies. The article provides detailed financial data, analyst ratings, and a comprehensive list of recent company news and insider transactions, indicating active development in its drug pipeline and significant insider buying and selling activities.
New lupus and arthritis drug data to be unveiled at Cullinan Immunology Day
Cullinan Therapeutics will host an Immunology Day on June 10, 2026, to showcase new and updated clinical data for its lead immunology programs, CLN-978 and velinotamig. The event will detail results from over 30 patients in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies for CLN-978, including initial multi-dose cohort data for RA, and initial multi-dose data for velinotamig in treatment-refractory autoimmune diseases. This aims to validate the potential of their T cell engagers in autoimmune diseases, with management and key opinion leaders presenting.
Behavioral Patterns of CGEM and Institutional Flows
This article from Stock Traders Daily analyzes Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting a weak near-term sentiment that could precede shifts in its mid and long-term outlook. It identifies a mid-channel oscillation pattern and offers three AI-generated trading strategies with specific entry, target, and stop-loss levels for different risk profiles. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for the stock.
Cullinan Therapeutics Receives FDA Orphan Drug Designation
Cullinan Therapeutics has received FDA Orphan Drug Designation for CLN-049, a novel FLT3xCD3 T cell engager, for treating relapsed/refractory acute myeloid leukemia (AML). This designation highlights the urgent need for new therapies in AML, especially for patients with TP53-mutated AML who face poor prognoses. CLN-049 is designed to target FLT3-expressing leukemia cells regardless of mutational status and is currently undergoing Phase 1 clinical trials.
Stifel reiterates Cullinan Oncology stock rating on trial data
Stifel maintained a Buy rating and a $28.00 price target for Cullinan Oncology Inc. after previewing abstract data for its CLN-978 trial. Initial results for systemic lupus erythematosus and rheumatoid arthritis patients showed only mild side effects and suggest a competitive product profile, with more comprehensive data expected in June 2026. This positive outlook, coupled with other recent favorable analyst ratings and an Orphan Drug Designation for CLN-049, indicates continued confidence in Cullinan's pipeline and strategic direction.
FDA grants orphan drug status to Cullinan’s CLN-049 for AML
Cullinan Therapeutics (NASDAQ:CGEM) has been granted Orphan Drug Designation by the FDA for CLN-049, its investigational treatment for relapsed/refractory acute myeloid leukemia (AML). This designation provides incentives such as tax credits and potential market exclusivity. The drug is currently in Phase 1 trials and previously received Fast Track designation for the same condition.
FDA grants orphan status to CLN-049 for relapsed or refractory AML patients
Cullinan Therapeutics announced that the FDA granted Orphan Drug Designation to CLN-049, a novel FLT3xCD3 T cell engager, for treating relapsed/refractory acute myeloid leukemia (AML). This designation recognizes the urgent unmet need for new therapies in AML patients, especially those with TP53-mutated disease, and follows promising Phase 1 clinical trial results for CLN-049. Despite the positive regulatory news, Cullinan Therapeutics' stock (CGEM) declined, indicating a notable negative market reaction.
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
Cullinan Therapeutics announced it will present initial clinical data for CLN-978, a subcutaneously administered CD19xCD3 T cell engager, at the EULAR 2026 Congress. The data from two Phase 1 studies (OUTRACE RA and OUTRACE SLE) showed a favorable safety profile, robust B cell depletion, and early signals of promising clinical activity in patients with rheumatoid arthritis and systemic lupus erythematosus. CLN-978 is a wholly owned asset with potential as a convenient, off-the-shelf therapeutic option for autoimmune diseases.
Alzheimer's and cancer: 10 trial drugs trace back to one antibody lab
MindWalk Holdings Corp. announced that over 20 partner-owned drug programs, originating from their antibody discovery work, have reached clinical trials, with ten currently in active Phase 1-3 trials for conditions like oncology, immunology, neurology, and infectious diseases. The company highlights its proprietary HYFT® biological intelligence infrastructure and B cell Llama™ camelid nanobody discovery platform as key drivers behind these successes, emphasizing the integration of AI with their wet-lab capabilities. Featured clinical-stage programs include ANX005 for Guilláin-Barré Syndrome and PMN310 for Alzheimer’s disease.
Cullinan trial drug depletes B cells in refractory arthritis and lupus
Cullinan Therapeutics will present initial Phase 1 clinical data for its subcutaneous CD19xCD3 T cell engager, CLN-978, at the EULAR 2026 Congress. The data from OUTRACE RA and OUTRACE SLE studies in treatment-refractory rheumatoid arthritis and moderate to severe systemic lupus erythematosus show favorable safety, robust B cell depletion, and early signals of clinical activity. Updated data, including additional patients, will be shared in a poster session on June 6, 2026.
(CGEM) Movement Within Algorithmic Entry Frameworks
The article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) using algorithmic entry frameworks. It highlights a weak near-term sentiment but strong mid and long-term outlook, with an exceptional 65.0:1 risk-reward setup targeting an 18.4% gain. Three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—are provided, along with multi-timeframe signal analysis indicating support and resistance levels.
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Cullinan Therapeutics announced its first-quarter 2026 financial results and provided a comprehensive corporate update. Key highlights include upcoming presentations of initial clinical data for CLN-978 in SLE and RA at the EULAR 2026 Congress in June, FDA acceptance of the zipalertinib NDA for EGFR ex20ins NSCLC with a PDUFA target date of February 27, 2027, and a strong cash position of $393.3 million extending into 2029. The company is advancing multiple clinical programs in both immunology and oncology, with several significant milestones anticipated throughout 2026.
Cullinan Therapeutics (CGEM) logs Q1 loss as FDA accepts zipalertinib NDA and cash tops $351.9M
Cullinan Therapeutics (CGEM) reported a Q1 2026 net loss of $49.661 million, driven by significant investment in its autoimmune and oncology programs. Despite the loss, the company's financial position remains strong with $351.9 million in cash, cash equivalents, and short-term investments, expected to fund operations for at least twelve months. Key developments include the FDA's acceptance of a new drug application for zipalertinib in NSCLC, with a target action date of February 27, 2027, and the completion of enrollment for a Phase 3 trial of the same drug.
Cullinan Therapeutics (CGEM) posts Q1 loss, advances autoimmune and cancer pipeline
Cullinan Therapeutics reported a Q1 2026 net loss of $49.7 million, with cash reserves of $393.3 million, expected to fund operations into 2029. The company highlighted significant pipeline progress, including the FDA's acceptance of the zipalertinib NDA for EGFR ex20ins NSCLC with a PDUFA date in February 2027, and upcoming data readouts for multiple T cell engager programs in autoimmune diseases and oncology. Despite ongoing losses, the company maintains a strong financial position and anticipates several clinical and regulatory milestones in 2026 and 2027.
Cullinan Therapeutics (NASDAQ: CGEM) CSO sells 8,000 shares, exercises 4,000 options
Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, executed an exercise-and-sell transaction involving 8,000 shares of Common Stock at weighted average prices of $14.60 and $15.58. Concurrently, she exercised stock options for 4,000 shares at $4.30 each. These transactions were performed under a pre-established Rule 10b5-1 trading plan dated August 7, 2025.
How (CGEM) Movements Inform Risk Allocation Models
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) using AI models, highlighting weak near and mid-term sentiment despite a positive long-term outlook. It presents exceptional risk-reward short setups and outlines three distinct trading strategies: a Position Trading Strategy (LONG), a Momentum Breakout Strategy (BREAKOUT), and a Risk Hedging Strategy (SHORT). The analysis provides entry zones, targets, and stop losses based on multi-timeframe signal analysis.
Cullinan Therapeutics (CGEM) outlines 2026 virtual annual meeting
Cullinan Therapeutics (CGEM) has announced its 2026 virtual annual meeting for June 16, 2026, where stockholders will vote on re-electing two Class III directors, ratifying KPMG LLP as the independent auditor, and approving executive compensation. The meeting will address key corporate governance matters, including director appointments, financial oversight, and executive pay packages. Key figures such as CEO Nadim Ahmed's 2025 compensation and the company's shares outstanding are detailed.
FDA starts review of new lung cancer drug, decision due Feb. 2027
The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for zipalertinib, a drug developed by Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics, for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The decision date for approval is set for February 27, 2027. This submission is supported by positive data from the Phase 2b REZILIENT1 clinical trial, which demonstrated clinically meaningful and durable responses in patients.
Cullinan Therapeutics' NDA For Zipalertinib Accepted By FDA
The FDA has accepted Cullinan Therapeutics' New Drug Application for zipalertinib to treat non-small cell lung cancer with EGFR exon 20 insertion mutations, setting a PDUFA target action date of February 27, 2027. This application is supported by positive Phase 2b data from the REZILIENT1 trial, which demonstrated a strong objective response rate. Following the announcement, Cullinan Therapeutics' shares saw a gain of over 2% in pre-market trading.
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) has received a consensus "Moderate Buy" recommendation from analysts, with an average one-year price target of $29.56, suggesting significant upside from its current share price of $15.21. The biopharmaceutical company recently reported better-than-expected earnings and is advancing multiple Phase I oncology programs. While institutional investors hold a large portion of the shares, insiders have been net sellers over the past 90 days.
How Cullinan Oncology Inc. (CGEM) Affects Rotational Strategy Timing
The article analyzes Cullinan Oncology Inc. (CGEM) using AI models, indicating strong sentiment across all time horizons. It provides institutional trading strategies including position trading (long), momentum breakout, and risk hedging (short), along with multi-timeframe signal analysis. The analysis identifies key support and resistance levels for CGEM, suggesting specific entry and exit points for various trading approaches.
CGEM SEC Filings - Cullinan Oncology Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Cullinan Oncology (CGEM) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It highlights key events such as clinical data updates for CLN-049 and CLN-978, financial results, and corporate actions. The platform also offers AI-powered summaries and sentiment analysis for these regulatory documents to assist investors in analyzing CGEM's progress and strategic direction.
CGEM SEC Filings - Cullinan Oncology Inc 10-K, 10-Q, 8-K Forms
This page provides access to Cullinan Oncology Inc.'s (CGEM) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material event reports (8-K), and insider trading forms. It highlights recent filings detailing financial results, clinical trial updates for pipeline assets like CLN-049 and CLN-978, and corporate actions such as the discontinuation of certain programs. The platform also offers AI-powered summaries and impact analysis for easier interpretation of these regulatory documents.
CGEM SEC Filings - Cullinan Oncology Inc 10-K, 10-Q, 8-K Forms
This page provides access to Cullinan Oncology Inc. (CGEM) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms, with AI-powered summaries. Recent filings include details on executive stock option grants and sales, and significant ownership disclosures by investment groups. The platform aims to offer comprehensive data for investors tracking CGEM's biopharmaceutical developments and corporate actions.
